Symbols

MED

Medifast·NYSE

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 3

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

Revenue Beats Expectation

Price Hits 52-week Low

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About MED

Medifast, Inc.

A manufacturer of weight and disease management products and other health and diet products

Industry

Healthcare Providers and Services

Established Date

Listing Date

08/25/2006

Exchange

New York Stock Exchange

Full-time Employees

380

Fiscal Year Ends

12-31

Website

www.medifastinc.com

Security Type

Common stock

Office address

100 International Drive, Baltimore, Maryland 21202

Business

Introduction

Medifast, Inc., was incorporated in Delaware in 1989. The company's business is mainly carried out through its wholly-owned subsidiaries, Including Jason Pharmaceuticals, Inc., OPTAVIA LLC, Jason Enterprises, Inc., Jason Properties, LLC, OPTAVIA (Hong Kong) Limited, and OPTAVIA Health Consultation (Shan ghai) Co., Ltd。The company is known for its health and wellness, and its habit-based, coach-guided lifestyle solution OPTAVIA has been well received. The company, located in Owings Mills, Maryland, has a modern, U.S. Food and Drug Administration-approved manufacturing facility. The company sells a variety of weight loss, weight management and healthy living products based on its proprietary formulas in three series: Essential Fuelings, OPTAVIA ASCEND and OPTAVIA ACTIVE.

Company Financials

EPS

MED has released its 2025 Q4 earnings. EPS was reported at -1.65, versus the expected -0.45, missing expectations. The chart below visualizes how MED has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

MED has released its 2025 Q4 earnings report, with revenue of 75.10M, reflecting a YoY change of -36.90%, and net profit of -18.12M, showing a YoY change of -2362.05%. The Sankey diagram below clearly presents MED's revenue sources and cost distribution.